Logan Capital Management Inc. Acquires 14,376 Shares of Sanofi $SNY

Logan Capital Management Inc. raised its holdings in shares of Sanofi (NASDAQ:SNY) by 10.8% during the fourth quarter, HoldingsChannel reports. The fund owned 147,363 shares of the company’s stock after purchasing an additional 14,376 shares during the quarter. Logan Capital Management Inc.’s holdings in Sanofi were worth $7,141,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of SNY. Mondrian Investment Partners LTD bought a new stake in Sanofi during the 3rd quarter valued at $171,742,000. Raymond James Financial Inc. increased its holdings in shares of Sanofi by 81.3% in the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after purchasing an additional 2,635,867 shares during the period. Capital Research Global Investors bought a new position in shares of Sanofi in the fourth quarter worth $79,960,000. Franklin Resources Inc. increased its holdings in shares of Sanofi by 29.7% in the fourth quarter. Franklin Resources Inc. now owns 5,100,097 shares of the company’s stock worth $247,151,000 after purchasing an additional 1,168,339 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in shares of Sanofi by 422.1% in the third quarter. BNP Paribas Financial Markets now owns 1,062,809 shares of the company’s stock worth $50,165,000 after purchasing an additional 859,246 shares during the period. Institutional investors own 14.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SNY. Morgan Stanley set a $52.00 price target on shares of Sanofi in a report on Friday, May 1st. Argus raised shares of Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Bank of America cut shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. Wall Street Zen cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $51.00.

Sanofi Stock Up 1.2%

SNY opened at $44.11 on Friday. The stock has a market cap of $106.94 billion, a PE ratio of 12.32, a P/E/G ratio of 1.07 and a beta of 0.34. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. Sanofi has a 52 week low of $42.28 and a 52 week high of $52.68. The business’s fifty day simple moving average is $45.21 and its 200 day simple moving average is $46.56.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were paid a $2.4225 dividend. This is a boost from Sanofi’s previous annual dividend of $2.04. This represents a yield of 559.0%. The ex-dividend date of this dividend was Monday, May 4th. Sanofi’s payout ratio is currently 49.16%.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.